With the launch of its XealTM abutment surface and TiUltraTM implant surface this year, Nobel Biocare recently initiated the MucointegrationTM era for implant dentistry. Now, evidence supporting these pioneering surfaces including clinical data has become available in a special supplement of the journal Clinical Implant Dentistry and Related Research (CIDRR).
Building on the scientific track record of the TiUniteTM surface, scientific research has been a key driving force behind the development of Xeal and TiUltra. The CIDRR supplement contains seven publications that include in vitro, pre-clinical and clinical studies conducted by researchers around the globe over the last five years. They have focused on how clinical and biological needs must be balanced, surface chemistry can enhance tissue integration as well as the Mucointegration™ concept. Overall, they provide a unique insight into the extensive research behind these surfaces. Promising results were found by a randomized controlled clinical study from the Brånemark Clinic in Gothenburg with two years of follow-up. It showed better soft tissue parameters, such as statistically significant greater mucosa height when using the new abutment surfaces over machined titanium abutments.[i]
With their unique surface chemistry and topography, Xeal and TiUltra were introduced with the goal to optimize early tissue integration and long-term tissue stability. Both surfaces are currently available in CE markets and will be released to dental professionals in other regions throughout 2019 following clearance, licensing or registration. Extending their benefits to the next generation of implants and abutments, they will also be an integral part of the company’s upcoming Nobel Biocare N1TM implant system.
Hans Geiselhöringer, President of Nobel Biocare Systems commented: “The new CIDRR supplement impressively shows our commitment to scientific documentation and product validation when bringing new solutions to the market. At Nobel Biocare, we believe that the Mucointegration™ concept is the next milestone in implantology for achieving both immediacy and longevity for successful treatment outcomes. Having launched this next generation of dental implant and abutment surfaces with such a wealth of scientific information already available at market release, we are once again confirming our role as a company that puts science first for the benefit of patients.”
All seven studies from the CIDRR supplement are available for download from nobelbiocare.com/surface. There, dental professionals can also find more information about the clinical benefits and availability of Xeal and TiUltra.
About Nobel Biocare
Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive® and NobelParallel™and ceramic implant NobelPearl™*) a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), digital solutions for treatment planning and guided surgery (NobelClinician® and DTX Studio™ suite) as well as biomaterials. Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at four sites located in the United States, Sweden and Japan. Products and services are available in over 80 countries through subsidiaries and distributors.
[i] A New Era in Mucointegration and Osseointegration Driven by Surface Chemistry. Clin Implant Dent Relat Res. 2019; Vol. 21, Issue S1, pages 1-68